BMO Capital Reiterates Outperform on Gilead Sciences (GILD) Amid 'Potential HHS HIV Funding Cuts'
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $115.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
